<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663323</url>
  </required_header>
  <id_info>
    <org_study_id>MER/EX</org_study_id>
    <nct_id>NCT02663323</nct_id>
  </id_info>
  <brief_title>Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System</brief_title>
  <acronym>MeRes-1 Extend</acronym>
  <official_title>MeRes-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meril Life Sciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meril Life Sciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MeRes-1 Extend study is designed as prospective, multinational, multicentre, single arm, open
      label, pilot study to assess the safety and performance of the MeRes100 Sirolimus Eluting
      Bioresorbable Vascular Scaffold System (BRS) in subjects with de novo native coronary artery
      lesions. 64 subjects will be enrolled from the 8 centers located in Asia Pacific, Europe,
      Brazil and South Africa. Primary outcome of study will be Proportion of population reporting
      Major Adverse Cardiac Events at 6 months from the day of index Procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Clinical Endpoint: Proportion of population reporting with Major Adverse Cardiac Event at 6 months from the day of index procedure.</measure>
    <time_frame>6 Month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Proportion of population reporting with Ischemia Driven Major Adverse Cardiac Event (ID MACE) reporting at 6 months (180 days) from the day of index procedure</measure>
    <time_frame>6 Month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>MeRes100 - BRS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System</intervention_name>
    <arm_group_label>MeRes100 - BRS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria:

          1. Male or female subjects ≥ 18 years of age

          2. Subject is able to sign written Informed Consent Form (ICF)

          3. Subjects with symptomatic myocardial ischemia, chronic stable angina

          4. The patient has planned intervention of a single de novo lesion in native epicardial
             vessel

          5. Subject who is an acceptable candidate for Coronary Artery Bypass Grafting (CABG)

          6. Subject is not participating in any other clinical investigation/study and agrees not
             to participate in any other clinical investigation/study for a period of 3 years
             following the index procedure.

          7. Subject must agree to undergo all clinical investigation plan-required follow-up
             visits, angiograms and OCT as per protocol.

        Angiographic Inclusion Criteria:

          1. Subject with maximum two treatable de novo lesions located maximum one per native
             epicardial vessel located in major artery or branch, with reference vessel diameter
             between 2.75, 3.00 and 3.5 mm by on line QCA.

          2. Target lesion length ≤ 20 mm.

          3. Subjects with Lesion(s), with a visually estimated stenosis of ≥ 50% and &lt; 100% with a
             TIMI flow of ≥ 1.

        Exclusion Criteria:

        General Exclusion Criteria:

          1. Subjects unable to provide written informed consent.

          2. Pregnant or nursing mother and those who plan pregnancy during the clinical
             investigation (female patients must have a negative pregnancy test done within 7 days
             prior to the index procedure and effective contraceptive must be used during
             participation in this clinical investigation).

          3. Subjects with known allergy to Poly-L-Lactide (PLLA), Poly-D,L-Lactide (PDLLA),
             Sirolimus (Rapamycin) or its any analog or derivative, clopidogrel, ticlopidine,
             prasugrel, contrast media, platinum, ticagrelor and any drug in dual antiplatelet
             therapy including aspirin, both heparin and bivalirudin.

          4. Subject diagnosed with Acute Myocardial Infarction (AMI) within 7 days preceding the
             index procedure, as indicated by elevated levels of cardiac enzymes and/or ST segment
             changes in Electro Cardio Gram (ECG).

          5. Subject with history of previous revascularization procedures including CABG and
             Percutaneous Coronary Intervention (PCI).

          6. Subject with vascular aneurysms, cardiac arrhythmias, congestive cardiac failure
             having LVEF &lt; 30%, cardiac tamponade.

          7. Recipient of an organ in an organ transplant procedure or is on a waiting list for any
             organ transplant.

          8. Subjects receiving immunosuppression therapy or having known immunosuppressive or
             autoimmune disease.

          9. Subjects with history of stroke, Cerebro Vascular Accident (CVA) or Transient Ischemic
             neurological Attack (TIA). Patients with renal insufficiency where creatinine levels
             are more than 1.3 mg/dl, known aplastic anaemia, chronic liver disease, platelet count
             &lt;100,000 cells/mm3, a WBC of &lt; 3,000 cells/mm3.

         10. Subjects planned for elective surgery within the first 12 months after the procedure
             that will require discontinuing dual antiplatelet therapy

         11. Subject has a history of bleeding diathesis or coagulatory disease, refuses blood
             transfusion, significant gastrointestinal or urinary bleed within the past 12 months.

         12. Subject having extensive peripheral vascular disease that precludes safe 6F sheath
             insertion.

         13. Subject having a history of paradoxical exercise induced vasoconstriction that is
             consistent with myocardial bridging in the coronary anatomy.

         14. Subjects participating in another clinical investigation.

         15. Subjects with short life expectancy such as cancer, Human Immunodeficiency Virus
             (HIV)/Acquired Immune Deficiency Syndrome (AIDS), or other co-morbid conditions that
             would limit compliance with the follow-up schedule of the study.

        Angiographic Exclusion Criteria:

          1. Subjects who are non-candidates for PCI.

          2. Any of the target lesions meets any of the following criteria:

               1. Aorto-ostial location (within 3 mm)

               2. Lesion located in left main coronary artery

               3. Lesion located within 2 mm of origin of the LAD or LCx

               4. Lesion that involves a bifurcation with a side branch ≥ 2mm in diameter and
                  ostial lesion &gt; 40% stenosed by visual estimation or side branch requiring
                  intervention

               5. Total occlusion (TIMI Flow 0), prior to wire crossing

               6. Extreme tortuosity proximal to or within the lesion

               7. Lesions having heavy calcification

               8. Extreme angulation (≥ 90 %) proximal to or within the lesion

          3. Evidence of previous revascularization:

               1. Previous PCI with or without restenosis from previous intervention

               2. Arterial or venous graft with or without lesion located within the graft or
                  distal to a diseased arterial or saphenous vein graft

          4. The target vessel contains visible thrombus.

          5. Another (clinically significant or potentially significant) lesion left untreated
             within target vessels (including side branch) or another significant vessel.

          6. Subject requiring or potentially requiring interventional procedures other than
             pre-dilatation and study device implantation and post dilatation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Alexandre Abizaid</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dante Pazzanese Hospital, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mr. Imrankhan Lohani</last_name>
    <phone>+912230732400</phone>
    <phone_ext>510</phone_ext>
    <email>Imrankhan.Lohani@merillife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Alexandre Abizaid, MD</last_name>
      <email>aabizaid@uol.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medistra Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>12950</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Teguh Santoso, MD</last_name>
      <email>tsantoso@cbn.net.id</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic of Cardiology</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Sasko Kedev, MD</last_name>
      <email>skedev@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Rosli Mohd. Ali, MD</last_name>
      <email>rosli@ijn.com.my</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Indonesia</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>MeRes-1 Extend</keyword>
  <keyword>MeRes100</keyword>
  <keyword>Sirolimus Eluting Bioresorbable Vascular Scaffold System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

